{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:28:35Z","timestamp":1794000515502,"version":"4.8.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.metabol.2026.156808","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:19:25Z","timestamp":1792646365000},"page":"156808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["miR-150-5p promotes MASH progression through regulation of CTH-associated sulfur and redox metabolism"],"prefix":"10.1016","volume":"185","author":[{"given":"Lexuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangshuo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruike","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengxiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156808_bb0005","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.metabol.2026.156808_bb0010","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2026.156808_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-050324-124753","article-title":"Metabolic dysfunction-associated Steatotic liver disease and metabolic dysfunction-associated steatohepatitis-related fibrosis: therapeutic options and approaches to treatment","volume":"77","author":"Tincopa","year":"2026","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2026.156808_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156044","article-title":"Expanding diagnostic and therapeutic horizons for MASH: comparison of the latest and conventional therapeutic approaches","volume":"161","author":"Anastasiou","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156808_bb0030","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(25)02276-7","article-title":"Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"407","author":"Noureddin","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156808_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(25)00979-1","article-title":"Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"406","author":"Loomba","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156808_bb0040","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156808_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2026.156808_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-beta agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156808_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1053\/j.gastro.2025.03.010","article-title":"Regulation of hepatic stellate cell phenotypes in metabolic dysfunction-associated steatohepatitis","volume":"169","author":"Kisseleva","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2026.156808_bb0060","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.metabol.2026.156808_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2026.156808_bb0070","article-title":"MiR-150 in HTLV-1 infection and T-cell transformation","volume":"13","author":"D'Agostino","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2026.156808_bb0075","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.celrep.2017.08.065","article-title":"miR-150-mediated Foxo1 regulation programs CD8+ T cell differentiation","volume":"20","author":"Ban","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.metabol.2026.156808_bb0080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jcmm.16119","article-title":"Extracellular vesicles-derived miR-150-5p secreted by adipose-derived mesenchymal stem cells inhibits CXCL1 expression to attenuate hepatic fibrosis","volume":"25","author":"Du","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0085","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep4.1677","article-title":"Identification of a microRNA-E3 ubiquitin ligase regulatory network for hepatocyte death in alcohol-associated hepatitis","volume":"5","author":"Fan","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2026.156808_bb0090","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-18-4044","article-title":"LncRNA SNHG10 facilitates hepatocarcinogenesis and metastasis by modulating its homolog SCARNA13 via a positive feedback loop","volume":"79","author":"Lan","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.metabol.2026.156808_bb0095","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/liv.13700","article-title":"Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties","volume":"38","author":"Santangelo","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2026.156808_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00484","article-title":"Transcriptional repression of CYP3A4 by increased miR-200a-3p and miR-150-5p promotes steatosis","volume":"10","author":"Huang","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.metabol.2026.156808_bb0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.bbrc.2017.10.149","article-title":"MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator","volume":"494","author":"Zhuge","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2026.156808_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119631","article-title":"Extracellular vesicles as markers of liver function: optimized workflow for biomarker identification in liver disease","volume":"24","author":"Paluschinski","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156808_bb0115","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.numecd.2016.08.004","article-title":"Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: clinical implications","volume":"26","author":"Di Mauro","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2026.156808_bb0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/1440-1681.13497","article-title":"Sodium butyrate ameliorates non-alcoholic fatty liver disease by upregulating miR-150 to suppress CXCR4 expression","volume":"48","author":"Zhang","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.metabol.2026.156808_bb0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2036.2010.04366.x","article-title":"Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease","volume":"32","author":"Estep","year":"2010","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.metabol.2026.156808_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1152\/physrev.00028.2021","article-title":"Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs","volume":"103","author":"Cirino","year":"2023","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2026.156808_bb0135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11434-014-0722-7","article-title":"Deficiency of cystathionine gamma-lyase and hepatic cholesterol accumulation during mouse fatty liver development","volume":"60","author":"Mani","year":"2015","journal-title":"Sci Bull"},{"key":"10.1016\/j.metabol.2026.156808_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/ars.2010.3781","article-title":"The quantitative significance of the transsulfuration enzymes for H2S production in murine tissues","volume":"15","author":"Kabil","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.metabol.2026.156808_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.niox.2024.08.001","article-title":"Cystathionine gamma-lyase deficiency exaggerates diethylnitrosamine-induced liver damage in mice","volume":"151","author":"Ligi","year":"2024","journal-title":"Nitric Oxide Biol Chem"},{"key":"10.1016\/j.metabol.2026.156808_bb0150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/ars.2016.6773","article-title":"Cystathionine \u03b3-lyase deficiency exacerbates CCl4-induced acute hepatitis and fibrosis in the mouse liver","volume":"27","author":"Ci","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.metabol.2026.156808_bb0155","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/hep.32577","article-title":"Hepatocellular cystathionine \u03b3 lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor","volume":"76","author":"Xu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2026.156808_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-01829-6","article-title":"FOXC1 promotes HCC proliferation and metastasis by upregulating DNMT3B to induce DNA hypermethylation of CTH promoter","volume":"40","author":"Lin","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.metabol.2026.156808_bb0165","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cellsig.2012.02.003","article-title":"Sp1 is involved in regulation of cystathionine \u03b3-lyase gene expression and biological function by PI3K\/Akt pathway in human hepatocellular carcinoma cell lines","volume":"24","author":"Yin","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.metabol.2026.156808_bb0170","article-title":"Hepatocyte FoxO1 depletion exacerbates hepatic inflammation in MASH by targeting cystathionine \u03b3-lyase","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep-UK"},{"key":"10.1016\/j.metabol.2026.156808_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.03.013","article-title":"DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates","volume":"35","author":"Qu","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156808_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156757","article-title":"Hepatic MED1 disruption ameliorates obesity-related fatty liver by attenuating SREBP1-driven lipogenesis","volume":"184","author":"Dai","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156808_bb0185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res"},{"key":"10.1016\/j.metabol.2026.156808_bb0190","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1126\/science.1121158","article-title":"The widespread impact of mammalian MicroRNAs on mRNA repression and evolution","volume":"310","author":"Farh","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.metabol.2026.156808_bb0195","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cell.2010.03.009","article-title":"Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP","volume":"141","author":"Hafner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2026.156808_bb0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature08170","article-title":"Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps","volume":"460","author":"Chi","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156808_bb0205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.metabol.2026.156808_bb0210","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature07242","article-title":"The impact of microRNAs on protein output","volume":"455","author":"Baek","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2026.156808_bb0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2026.156808_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107837","article-title":"Nuclear miR-150 enhances hepatic lipid accumulation by targeting RNA transcripts overlapping the promoter","volume":"26","author":"Luo","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.metabol.2026.156808_bb0225","doi-asserted-by":"crossref","first-page":"G101","DOI":"10.1152\/ajpgi.00220.2009","article-title":"Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation","volume":"298","author":"Venugopal","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2026.156808_bb0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3892\/ijmm.2013.1356","article-title":"Activation of hepatic stellate cells is suppressed by microRNA-150","volume":"32","author":"Zheng","year":"2013","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0235","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/jcmm.14068","article-title":"Long noncoding RNA HOTTIP mediates SRF expression through sponging miR-150 in hepatic stellate cells","volume":"23","author":"Zheng","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0240","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11910","article-title":"Identification of miRNA-target gene regulatory networks in liver fibrosis based on bioinformatics analysis","volume":"9","author":"Tai","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.metabol.2026.156808_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103809","article-title":"Metabolic dysfunction-associated steatohepatitis reduces hepatic H(2)S-producing enzymes altering persulfidome composition","volume":"86","author":"Shen","year":"2025","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2026.156808_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087019","article-title":"Selective hepatic Cbs knockout aggravates liver damage, endothelial dysfunction and ROS stress in mice fed a western diet","volume":"24","author":"Lambooy","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2026.156808_bb0255","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-10-60","article-title":"High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the transsulphuration pathway","volume":"10","author":"Bravo","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2026.156808_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2022.111507","article-title":"High dietary methionine intake may contribute to the risk of nonalcoholic fatty liver disease by inhibiting hepatic H2S production","volume":"158","author":"Yang","year":"2022","journal-title":"Food Res Int"},{"key":"10.1016\/j.metabol.2026.156808_bb0265","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1139\/cjpp-2013-0106","article-title":"High-fat diet stimulates hepatic cystathionine \u03b2-synthase and cystathionine \u03b3-lyase expression","volume":"91","author":"Hwang","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.metabol.2026.156808_bb0270","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201705RR","article-title":"Exogenous hydrogen sulfide alleviates hepatic endoplasmic reticulum stress via SIRT1\/FoxO1\/PCSK9 pathway in NAFLD","volume":"37","author":"Cui","year":"2023","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2026.156808_bb0275","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.ymthe.2025.04.024","article-title":"Gene-based therapies for steatotic liver disease","volume":"33","author":"Iakovleva","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.metabol.2026.156808_bb0280","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2026.156808_bb0285","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0290","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2026.156808_bb0295","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115495","article-title":"A phase 1\/2 trial of investigational Spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2026.156808_bb0300","article-title":"Novel vectors and approaches for gene therapy in liver diseases","volume":"3","author":"Maestro","year":"2021","journal-title":"Jhep Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:04:53Z","timestamp":1793999093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"alternative-id":["S0026049526003215"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156808","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miR-150-5p promotes MASH progression through regulation of CTH-associated sulfur and redox metabolism","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156808"}}